Christophe L. M. J. Verlinde

Christophe L. M. J. Verlinde

Auto-generated profile, based on publicly available information

Christophe L. M. J. Verlinde

Department of Biochemistry, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2008 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
FAFernán Agüero
Fernán Agüero
BABissan Al-Lazikani
Bissan Al-Lazikani
MAMartin Aslett
Martin Aslett
MBMatthew Berriman
Matthew Berriman
FBFrederick Buckner
Frederick Buckner
CVChristophe L. M. J. Verlinde
Christophe L. M. J. Verlinde

1 January 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
FHFrançoise Haeseleer
Françoise Haeseleer
ISIzabela Sokal
Izabela Sokal
CVChristophe L. M. J. Verlinde
Christophe L. M. J. Verlinde
HEHediye Erdjument-Bromage
Hediye Erdjument-Bromage
Paul TempstPaul Tempst
Paul Tempst
KPKrzysztof Palczewski
Krzysztof Palczewski
Five members of a novel Ca2+-binding protein subfamily (CaBP), with 46–58% sequence similarity to calmodulin (CaM), were identified in the vertebrate retina. Important differences between these Ca2+-binding proteins and CaM include alterations within their second EF-hand loop that render these motifs inactive in Ca2+ coordination and the fact that their central α-helixes are extended by one α-helical turn. CaBP1 and CaBP2 contain a consensus sequence for N-terminal myristoylation, similar to members of the recoverin subfamily and are fatty acid acylated in vitro. The patterns of expression differ for each of the various members. Expression of CaBP5, for example, is restricted to retinal rod and cone bipolar cells. In contrast, CaBP1 has a more widespread pattern of expression. In the brain, CaBP1 is found in the cerebral cortex and hippocampus, and in the retina this protein is found in cone bipolar and amacrine cells. CaBP1 and CaBP2 are expressed as multiple, alternatively spliced variants, and in heterologous expression systems these forms show different patterns of subcellular localization. In reconstitution assays, CaBPs are able to substitute functionally for CaM. These data suggest that these novel CaBPs are an important component of Ca2+-mediated cellular signal transduction in the central nervous system where they may augment or substitute for CaM.

1 July 1994 in Structure
Verified
Journal Article
Closed access
CVChristophe Lmj Verlinde
Christophe Lmj Verlinde
WHWim Gj Hol
Wim Gj Hol

1 April 2003 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
DCDong-Hui Chen
Dong-Hui Chen
ZBZoran Brkanac
Zoran Brkanac
CVChristophe L M J Verlinde
Christophe L M J Verlinde
XTXiao-Jian Tan
Xiao-Jian Tan
LBLaura Bylenok
Laura Bylenok
WRWendy H Raskind
Wendy H Raskind

1 February 2001 in Drug Resistance Updates
Verified
Journal Article
Closed access
CVChristophe L.M.J. Verlinde
Christophe L.M.J. Verlinde
VHVéronique Hannaert
Véronique Hannaert
CBCasimir Blonski
Casimir Blonski
MWMichèle Willson
Michèle Willson
JPJacques J. Périé
Jacques J. Périé
PMPaul Michels
Paul Michels

2 May 2010 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
KOKayode K Ojo
Kayode K Ojo
ELEric T Larson
Eric T Larson
KKKatelyn R Keyloun
Katelyn R Keyloun
LCLisa J Castaneda
Lisa J Castaneda
ADAmy E DeRocher
Amy E DeRocher
WVWesley C Van Voorhis
Wesley C Van Voorhis
A family of calcium-dependent protein kinases (CDPK) is present in apicomplexan parasites but not in animals, indicating their potential as targets for anti-parasitic drugs. Structural and functional studies on Toxoplasma gondii CDPK1 now reveal that this kinase is sensitive to a class of drugs called bumped kinase inhibitors, which can inhibit the parasite's growth and host cell invasion. New drugs are needed to treat toxoplasmosis. Toxoplasma gondii calcium-dependent protein kinases (TgCDPKs) are attractive targets because they are absent in mammals. We show that TgCDPK1 is inhibited by low nanomolar levels of bumped kinase inhibitors (BKIs), compounds inactive against mammalian kinases. Cocrystal structures of TgCDPK1 with BKIs confirm that the structural basis for selectivity is due to the unique glycine gatekeeper residue in the ATP-binding site. We show that BKIs interfere with an early step in T. gondii infection of human cells in culture. Furthermore, we show that TgCDPK1 is the in vivo target of BKIs because T. gondii expressing a glycine to methionine gatekeeper mutant enzyme show significantly decreased sensitivity to BKIs. Thus, design of selective TgCDPK1 inhibitors with low host toxicity may be achievable.